The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded a $886,805 definitive cost-no-fee contract from the National Heart, Lung, and Blood Institute to support the Vascular Interventions/Innovations and Therapeutic Advances program. Under this award, the University will conduct research into selective inhibitors of integrin outside-in signaling as a new generation of anti-thrombotics. The potential value of $886,805.38 reflects the full period of performance through the completion date of November 14, 2016. No set-aside designation was applied to this contract. The place of performance will be in Chicago, Illinois.
Generated 3/13/24, 10:06 AM